XUNFEIHEALTH (02506) has released its annual results for the period ending December 31, 2025. The company reported revenue of 915 million yuan, representing a year-on-year increase of 24.7%. Net loss attributable to owners narrowed by 51.1% to 64.788 million yuan. Gross profit rose by 14.2% to 462 million yuan.

Throughout 2025, the company actively expanded its market presence, resulting in continuous growth of its customer base. By the end of the year, it had provided products and services to more than 77,000 primary healthcare institutions across 806 districts and counties in 31 provinces, as well as over 600 tiered hospitals. This extensive market coverage highlights the technological leadership and market competitiveness of its AI healthcare products, as well as the efficiency of its sales and marketing system, laying a solid foundation for future rapid business growth.

Leveraging its advanced technological capabilities, broad customer base, and strong brand recognition, the company has steadily improved operational efficiency and capitalized on new profit opportunities through a coordinated commercialization strategy. In the fiscal year ending December 31, 2025, revenue increased by 24.7%, while gross profit grew by 14.2%. The gross profit margin stood at 50.5%, remaining at a reasonably high level.

As the company's product portfolio continues to expand and mature, revenue is expected to grow rapidly, while the overall gross margin is projected to remain relatively stable. Guided by its mission to become "an AI diagnostic assistant for every doctor and an AI health assistant for every individual," XUNFEIHEALTH has developed a suite of AI-powered diagnostic assistant products for governments, hospitals, and patients, as well as AI health assistant solutions, based on its industry-leading artificial intelligence technology and deep sector expertise. Its business is categorized into four segments: primary care solutions, regional solutions, hospital solutions, and patient management services.